



Advertisement

JOURNAL OF CLINICAL ONCOLOGY
Official Journal of the American Society of Clinical Oncology

Search for: **GO**

Limit by: All Topics All Years

Browse by **Subject** or **Issue**

Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

Journal of Clinical Oncology, Vol 26, No 22 (August 1), 2008: pp. 3749-3755
© 2008 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.14.3974

Amifostine Protects Against Cisplatin-Induced Ototoxicity in Children With Average-Risk Medulloblastoma

Maryam Fouladi, Murali Chintagumpala, David Ashley, Stewart Kellie, Sridharan Gururangan, Tim Hassall, Lindsey Gronewold, Clinton F. Stewart, Dana Wallace, Alberto Broniscer, Gregory A. Hale, Kimberly A. Kasow, Thomas E. Merchant, Brannon Morris, Matthew Krasin, Larry E. Kun, James M. Boyett, Amar Gajjar

From the Departments of Oncology, Biostatistics, Pharmaceutical Sciences, Radiological Sciences, St Jude Children's Research Hospital, Memphis, TN; Baylor College of Medicine, Houston, TX, Royal Children's Hospital, Melbourne, Australia; Children's Hospital at Westmead, Sydney, Australia; Royal Children's Hospital, Brisbane, Australia; and The Preston Robert Tisch Brain Tumor Center and Departments of Pediatrics and Surgery, Duke University Medical Center, Durham, NC

Corresponding author: Maryam Fouladi, MD, Department of Oncology, St Jude Children's Research Hospital, 332 North Lauderdale, Memphis, TN 38105-2794; e-mail: maryam.fouladi@stjude.org

Purpose: To determine the role of amifostine as a protectant against cisplatin-induced ototoxicity in patients with average-risk (AR) medulloblastoma treated with craniospinal radiotherapy and four cycles of cisplatin-based, dose-intense chemotherapy and stem-cell rescue.

Patients and Methods: The primary objective was to determine whether, in patients with AR medulloblastoma ($n = 62$), amifostine would decrease the need for hearing aids (defined as \geq grade 3 ototoxicity in one ear) compared with a control group ($n = 35$), 1 year from initiating treatment. Ninety-seven patients received craniospinal irradiation (23.4 Gy) followed by 55.8 Gy to the primary tumor bed using three-dimensional conformal technique, and four cycles of high-dose cyclophosphamide (4,000 mg/m²/cycle), cisplatin (75 mg/m²/cycle), and vincristine (two 1.5 mg/m² doses/cycle) and stem-cell rescue. When used, amifostine (600 mg/m²/dose) was administered as a bolus immediately before and 3 hours into the cisplatin infusion.

Results: The median age of the 97 patients was 8.7 years (range, 3.2 to 20.2 years). The study and control groups were similar in age and sex distribution. Amifostine was well-tolerated. One year after treatment initiation, 13 patients (37.1%) in the control group versus nine (14.5%; one-sided χ^2 test $P = .005$) of the amifostine-treated patients had at least grade 3 ototoxicity, requiring hearing aid in at least one ear.

Conclusion: Amifostine administered before and during the cisplatin infusion can significantly reduce the risk of severe ototoxicity in patients with AR medulloblastoma receiving dose-intense chemotherapy.

Supported in part by National Cancer Institute Grant No. P30 CA21765, the Pediatric Brain Tumor Foundation, the Noyes Brain Tumor Foundation, Musicians Against Childhood Cancer, the Ryan McGhee Foundation, and the American Lebanese Syrian Associated Charities.

This Article

- ▶ [Full Text](#)
- ▶ [Full Text \(PDF\)](#)
- ▶ [Purchase Article](#)
- ▶ [View Shopping Cart](#)
- ▶ [Alert me when this article is cited](#)
- ▶ [Alert me if a correction is posted](#)

Services

- ▶ [Email this article to a colleague](#)
- ▶ [Similar articles in this journal](#)
- ▶ [Similar articles in PubMed](#)
- ▶ [Alert me to new issues of the journal](#)
- ▶ [Save to my personal folders](#)
- ▶ [Download to citation manager](#)

Google Scholar

- ▶ [Articles by Fouladi, M.](#)
- ▶ [Articles by Gajjar, A.](#)

PubMed

- ▶ [PubMed Citation](#)
- ▶ [Articles by Fouladi, M.](#)
- ▶ [Articles by Gajjar, A.](#)

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

About JCO		Editorial Roster		Advertising Information		Librarians & Institutions		Rights & Permissions		Site Map
---------------------------	--	----------------------------------	--	---	--	---	--	--	--	--------------------------

Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
[Terms and Conditions of Use](#)



HighWire Press™ assists in the publication of JCO Online